162 related articles for article (PubMed ID: 38507187)
1. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
[TBL] [Abstract][Full Text] [Related]
2. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
[TBL] [Abstract][Full Text] [Related]
3. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.
Fitzgerald T; Melsheimer R; Lafeuille MH; Lefebvre P; Morrison L; Woodruff K; Lin I; Emond B
Biologics; 2021; 15():1-15. PubMed ID: 33442230
[TBL] [Abstract][Full Text] [Related]
4. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
[TBL] [Abstract][Full Text] [Related]
6. Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea.
Kim DW; Lee Y; Kim G; Kim SH; Cho DH; Choi J; Kwon YH; Park Y; Choi W; Park DI
Adv Ther; 2023 Mar; 40(3):1047-1061. PubMed ID: 36624354
[TBL] [Abstract][Full Text] [Related]
7. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.
Bhat S; Altajar S; Shankar D; Zahorian T; Robert R; Qazi T; Shah B; Farraye FA
J Manag Care Spec Pharm; 2020 Apr; 26(4):410-416. PubMed ID: 32223602
[TBL] [Abstract][Full Text] [Related]
8. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab.
Lin I; Melsheimer R; Bhak RH; Lefebvre P; DerSarkissian M; Emond B; Lax A; Nguyen C; Wu M; Young-Xu Y
Curr Med Res Opin; 2022 Apr; 38(4):613-627. PubMed ID: 35125053
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Shimizu T; Kawashiri SY; Sato S; Morimoto S; Minoda S; Kawazoe Y; Kuroda S; Tashiro S; Sumiyoshi R; Hosogaya N; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Aug; 99(32):e21480. PubMed ID: 32769882
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
[TBL] [Abstract][Full Text] [Related]
11. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
Takeuchi T; Nishikawa K; Yamada F; Ohshima S; Inoue M; Yoshioka Y; Yamanaka H
Mod Rheumatol; 2022 Jul; 32(4):718-727. PubMed ID: 34918129
[TBL] [Abstract][Full Text] [Related]
12. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
Alten R; Burmester GR; Matucci-Cerinic M; Salmon JH; Östör A; Ng KJ; Gerwien J; Zaremba-Pechmann L; Brnabic AJM; Fautrel B
Rheumatol Ther; 2023 Dec; 10(6):1575-1595. PubMed ID: 37755648
[TBL] [Abstract][Full Text] [Related]
16. Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.
Kearsley-Fleet L; Rokad A; Tsoi MF; Zhao SS; Lunt M; Watson KD; ; Hyrich KL
Rheumatology (Oxford); 2023 Dec; 62(12):3849-3857. PubMed ID: 36943379
[TBL] [Abstract][Full Text] [Related]
17. Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry.
Tesser J; Lin I; Shiff NJ; Chakravarty SD; Schmajuk G; Hammam N; Desai S
Clin Rheumatol; 2022 Aug; 41(8):2319-2327. PubMed ID: 35312895
[TBL] [Abstract][Full Text] [Related]
18. Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.
Yazici Y; Xie L; Ogbomo A; Ellis LA; Goyal K; Teeple A; Simsek I
Biologics; 2018; 12():127-134. PubMed ID: 30498332
[TBL] [Abstract][Full Text] [Related]
19. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
[TBL] [Abstract][Full Text] [Related]
20. Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.
Yin Y; McDermott C; Lockhart C
J Manag Care Spec Pharm; 2023 Sep; 29(9):985-998. PubMed ID: 37610110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
